Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy.
Results of long-term administration of L-threo-3,4-dihydroxyphenylserine (L-DOPS), a synthetic precursor of noradrenaline, in a patient with freezing gait and pure akinesia are reported. Effects were temporal and disappeared during a 16-month treatment period. It was recognized that pure akinesia is an early symptom of progressive supranuclear palsy (PSP). Previously, we reported results of short-term (4 weeks) administration of L-DOPS in this patient. We present the further clinical course of the patient, along with results of long-term (16 months) administration of L-DOPS.
Yamamoto
M
M
Department of Neurology, Kagawa Prefectural Central Hospital, Bancho, Takamatsu, Japan.
Fujii
S
S
Hatanaka
Y
Y
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D015103:Droxidopa / Q000627:therapeutic use*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood / Q000134:cerebrospinal fluid; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood / Q000134:cerebrospinal fluid; D008875:Middle Aged; D009069:Movement Disorders / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000503:physiopathology; D013494:Supranuclear Palsy, Progressive / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D015103:Droxidopa